New Triple-Threat treatment tested for tough prostate cancer
NCT ID NCT07226986
Summary
This study is testing a new three-drug combination for men with advanced prostate cancer that has spread and is no longer responding well to standard hormone-blocking pills. The goal is to see if adding an experimental drug called AMO959 to two existing treatments is safe and can better control the cancer. The study will involve about 123 men whose cancer has a specific marker called PSMA.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSMA-POSITIVE METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WITH PRIOR EXPOSURE TO ONE PRIOR ARPI WHO ARE CANDIDATES FOR TAXANE-BASED CHEMOTHERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGMalvern, Victoria, 3144, Australia
-
Novartis Investigative Site
RECRUITINGMurdoch, Western Australia, 6150, Australia
-
Novartis Investigative Site
RECRUITINGSapporo, Hokkaido, 060-8648, Japan
-
Novartis Investigative Site
RECRUITINGGranada, Andalusia, 18014, Spain
-
Novartis Investigative Site
RECRUITINGBarcelona, 08036, Spain
-
Rio Grande Urology
RECRUITINGEl Paso, Texas, 79912, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.